National Cheng-Kung University

Other

Dcb-usa LLC

Trai-Ming Yeh

Yung-Chun Chuang

Dar-Bin Shieh

Hsin-Wei Chen

Yee-Shin Lin

Yen-Chung Lai

Tzong-Shiann Ho

Shu-Ying Wang

Shu-Wen Wan

Chia-Yi Yu

The present invention relates to a composition of subunit dengue vaccine comprising a fusion protein of conjugating or connecting delta C nonstructural protein 1 (NS1&#x394;C or truncated NS1&#x394;C) to at least one polypeptides of NS3c (or truncated NS3c) and/or consensus envelope protein domain III (cEDIII), thereby enhancing better protection against DENV challenge and alleviating associated pathological effects.

Composition of subunit dengue vaccine

Disclosed herein is an anti-DENV antibody, a pharmaceutical composition comprising the same, and uses thereof. According to embodiments of the present disclosure, the anti-DENV antibody comprises a heavy chain variable region and a light chain variable region, in which the heavy chain variable region comprises amino acid sequences of SEQ ID NOs: 1-3, and the light chain variable region comprises amino acid sequences of SEQ ID NOs: 5-7.

Anti-dengue virus antibody, pharmaceutical composition comprising the same, and uses thereof

An antibody for activating plasminogen is provided. The antibody is produced from a hybridoma cell line deposited on Nov. 24, 2011 under accession number BCRC 960433 at Food Industry Research and Development Institute, 331 Shih-Pin Road, Hsinchu 300, Taiwan. The uses and producing method of the antibody, and an agent including the antibody used for treating stroke, myocardial infarction or syndromes cause by thrombus are also disclosed.

Plasminogen-activating antibody, use and producing method thereof and agent including the same

Growing community of inventors

Tainan, Taiwan

Trai-Ming Yeh